You are here: Industry Insights > Immunic

News List

EIB to support COVID-19 therapy with €24.5 million investment europeanpharmaceuticalreview
October 22, 2020
The European Investment Bank (EIB) will provide Immunic with up to €24.5 million to support the ongoing development of IMU-838, a potential COVID-19 therapy.
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19 prnewswire
September 30, 2020
Immunic, Inc. announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase 2 CALVID-1 trial of its selective oral DHODH inhibitor, IMU-838, in patients with moderate coronavirus disease 2019 (COVID-19).
Immunic Begins IMU-838, Oseltamivir Trial for COVID-19 americanpharmaceuticalreview
July 31, 2020
Immunic announced enrollment of the first patients in an investigator-sponsored phase 2 clinical trial of the company's selective oral DHODH inhibitor, IMU-838, for the treatment of patients with coronavirus disease 2019 (COVID-19).
Immunic Announces FDA Allowance of IMU-838 Trial americanpharmaceuticalreview
June 18, 2020
Immunic announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19) at centers
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 prnewswire
June 16, 2020
Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases.
Immunic Reports IMU-838 Demonstrates Preclinical Activity Against SARS-CoV-2 americanpharmaceuticalreview
April 24, 2020
Immunic reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Immunic Licenses IMU-856 from Daiichi Sankyo americanpharmaceuticalreview
January 13, 2020
Immunic announced its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo, has exercised its exclusive global option to license a group of compounds, designated by Immunic as IMU-856.